Workflow
疫苗销售下滑
icon
Search documents
美股异动丨莫德纳(MRNA.US)大跌超10%,下调2025年收入预期上限
Ge Long Hui· 2025-08-01 15:26
Core Viewpoint - Moderna's stock experienced a significant drop of over 10%, trading at $26.56, following the announcement of its second-quarter financial results which revealed a net loss of $825 million, or $2.13 per share, which was better than the expected loss of $2.97 per share [1] Financial Performance - The company's revenue from COVID-19 vaccine sales declined by 41% year-over-year, amounting to $140 million, which exceeded the expected revenue of $110 million [1] - In the same quarter of the previous year, Moderna reported a net loss of $1.3 billion, or $3.33 per share [1] Revenue Guidance - Due to delays in vaccine shipments to the UK, Moderna has revised its revenue guidance for 2025, now expecting annual revenue to be between $1.5 billion and $2.2 billion, a reduction of $300 million from earlier projections [1]